| Good Morning Wake-Up Watchlisters! While you're sippin coffee you'll see stock futures held steady on Wednesday ahead of a key inflation report. The CPI report is set for release at 8:30 a.m. and is expected to show annual inflation of 3.4% compared with 3.4% of February. Also, Delta Airlines kicked off earnings season (more on that below). With the key inflation report coming out, it's important to know how government reports could lead to big trading opportunities. Right now our Head Trading Tactician Bryan Bottarelli one of his favorite government loopholes for potential huge overnight profits. Click here to discover the "JOLTS" loophole. Here's a look at the top-moving stocks this morning. Delta Airlines (NYSE: DAL) Delta Air Lines is up 4.84% in premarket trading due to a bullish outlook for the second quarter, driven by strong travel demand. Despite worry over safety issues from several indicidents surrounding manufacurer Boeing, Delta anticipates an adjusted profit between $2.20 and $2.50 per share, surpassing analyst expectations. Around 950 Delta planes are Boeing models, but in recent years it has bought primarily from Airbus, including a January order for 20 big Airbus A350s. Delta aims for a 14% to 15% operating margin and a 5% to 7% increase in second-quarter revenue year-on-year, supported by a forecast of 4.7 billion global travelers in 2024. Earnings reports can often serve as a trigger for a stock's swing in either direction. However, the truth is there are plenty of opportunities to trade stocks AFTER earnings. Our Lead Technical Tactician Nate Bear follows what he calls the "post-earnings surge" for maximum potential gains. So far in 2024 he has a 100% win rate using this strategy on 27 trades. Click here to get Nate's next "One Ticker Payout" today. Moderna (Nasdaq: MRNA) Moderna is up 0.83% premarket due to positive trial results for its cancer vaccine developed in collaboration with Merck's Keytruda. This vaccine, aimed at head and neck cancer, demonstrates potential beyond melanoma, sparking optimism for accelerated approval processes. However, opinions on the trial's significance vary, with some analysts urging caution due to the small scale of the study. | 
No comments:
Post a Comment